Akrevia Therapeutics, a privately-held biopharmaceutical company focused on developing highly-potent, tumour-targeted immuno-oncology therapeutics, announced yesterday that it has named Joseph Farmer as its new Chief Operating Officer.
Farmer will lead Akrevia's business development, finance, administrative, and business operations functions. He will report to Rene Russo, PharmD, Akrevia's Chief Executive Officer.
Farmer is a biopharma executive with more than 20 years of industry experience. Prior to joining Akrevia, he most recently served as Senior Vice President, General Counsel, and Corporate Secretary at Tesaro, Inc. Prior to Tesaro, he was Chief Corporate Counsel and Assistant Secretary at Cubist Pharmaceuticals Inc.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886